GBCI:NYSEGlacier Bancorp, Inc. Analysis
Data as of 2026-05-19 - not real-time
$46.79
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Glacier Bancorp posted a 29% jump in net income to $82.1 million in Q1 2026, driven by a notable expansion in net interest margin. The bank’s revenue surged 39.7% year‑over‑year to $1.04 billion, underpinning an operating margin of 41.5% and a profit margin of 25.7%. With a trailing EPS of $2.14 and a forward EPS estimate of $3.65, earnings momentum appears strong. The stock trades at a price‑to‑earnings of 21.9, above the industry average of 16.7, yet a discounted cash‑flow model places fair value near $70.3, implying a ~20% upside to the current price of $46.79. The company offers a 2.82% dividend yield and a 77% payout ratio, supported by $1.39 billion in cash on hand. Technically, the price sits just above the 50‑day SMA ($46.56) but below the 20‑day SMA ($48.20), with a bearish MACD and a neutral RSI of 45.8, while volume remains stable around support at $45.44.
Volatility over the past 30 days is elevated at 26%, and a beta of 1.16 signals higher sensitivity to market swings, placing the stock in a medium‑risk bracket. The regional‑bank sector faces moderate regulatory scrutiny and interest‑rate exposure, though geographic concentration in the United States keeps currency risk low. The Fear & Greed Index reads “Extreme Greed,” reflecting strong market optimism that could fuel short‑term buying. Analyst consensus (6 analysts) rates the stock a Buy with a median target of $56.5, reinforcing the upside narrative. Given the earnings beat, attractive dividend, and valuation gap, the stock is positioned for upward movement in the coming months. Investors should monitor the MACD crossover and the $50.15 resistance level as potential catalysts for price acceleration.
Volatility over the past 30 days is elevated at 26%, and a beta of 1.16 signals higher sensitivity to market swings, placing the stock in a medium‑risk bracket. The regional‑bank sector faces moderate regulatory scrutiny and interest‑rate exposure, though geographic concentration in the United States keeps currency risk low. The Fear & Greed Index reads “Extreme Greed,” reflecting strong market optimism that could fuel short‑term buying. Analyst consensus (6 analysts) rates the stock a Buy with a median target of $56.5, reinforcing the upside narrative. Given the earnings beat, attractive dividend, and valuation gap, the stock is positioned for upward movement in the coming months. Investors should monitor the MACD crossover and the $50.15 resistance level as potential catalysts for price acceleration.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Q1 earnings beat with 29% net income increase
- Dividend yield of 2.82% with strong cash position
- Price near support at $45.44 offering limited downside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggests ~20% upside
- Revenue growth of 39.7% and expanding margins
- Analyst median target $56.5 indicating upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable dividend and high payout supported by cash
- Long-term undervaluation relative to DCF
- Strong operating profitability and regional market presence
Key Metrics & Analysis
Financial Health
Revenue Growth39.70%
Profit Margin25.70%
P/E Ratio21.9
ROE7.07%
ROA0.90%
P/B Ratio1.4
Op. Cash Flow$409.8M
Industry P/E16.7
Technical Analysis
TrendBullish
RSI45.8
Support$45.44
Resistance$50.15
MA 20$48.20
MA 50$46.56
MA 200$46.35
MACDBearish
VolumeStable
Fear & Greed Index89.61
Valuation
Fair Value$70.34
Target Price$56.50
Upside/Downside20.75%
GradeUndervalued
TypeBlend
Dividend Yield2.82%
Risk Assessment
Beta1.16
Volatility26.06%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.